Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection Yuen, M., Chan, H., Given, B., Hamilton, J., Schluep, T., Lewis, D. L., Lai, C., Locarnini, S., Lau, J. Y., Gish, R. G. WILEY-BLACKWELL. 2014: 1280A

View details for Web of Science ID 000345517000022